Citius Oncology Partners with EVERSANA for LYMPHIR Commercialization
ByAinvest
Thursday, Oct 16, 2025 8:51 am ET1min read
CTOR--
Citius Oncology has signed an exclusive commercialization agreement with EVERSANA to support the planned Q4 2025 launch of LYMPHIR, a therapy for relapsed or refractory cutaneous T-cell lymphoma. EVERSANA will provide integrated commercialization services, including medical information, pharmacovigilance, revenue cycle management, and data and analytics, to enhance launch readiness and market entry for LYMPHIR. This agreement marks a transformative milestone for Citius Oncology, allowing it to extend its commercial capabilities and strengthen its operational readiness for the launch of LYMPHIR.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet